Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R. Diamond, Sant P. Chawla, Anthony W. Tolcher, Patricia M. LoRusso, Joseph P. Eder, Martin Gutierrez, Kumar Sankhala, Prabhu Rajagopalan, Isabelle Genvresse, Simon Langer, Ron H.J. Mathijssen, Jaap Verweij, Ingmar Bruns, and Martijn P. Lolkema

In the original version of this article (1), errors exist in Tables 2, 3, and 4 and in the Results section. In Table 2, the bioavailability factor was listed for the oral solution instead of the liquid capsule formulation, which has a lower bioavailability of 38%, and thus the bioavailability factor in footnote "a" should list 2.6 instead of 2.7; also in Table 2, all five 90% credible interval values are for the oral solution instead of the liquid capsule formulation and should have been adjusted accordingly. In the Results section and in Table 3's footnote "a", the bioavailability of liquid capsule formation should be 38% instead of –31%. In Table 4, the 40% value for the Median MTD in mg for rCRM-20 should be 7.4 instead of 53.2. The errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret the errors.

Reference

1. Atrafi F, Boix O, Subbiah V, Diamon JR, Chawl SP, Tolcher AW, et al. A phase I study of an MPS1 inhibitor (BAY 1217389) in combination with paclitaxel using a novel randomized continual reassessment method for dose escalation. Clin Cancer Res 2021;27:6366–75.

Published online July 1, 2022.
Clin Cancer Res 2022;28:2969
doi: 10.1158/1078-0432.CCR-22-1792